BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19778851)

  • 21. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
    Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease in chronic myeloid leukaemia patients.
    Hochhaus A
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):159-78. PubMed ID: 11987922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
    Hughes T; Branford S
    Blood Rev; 2006 Jan; 20(1):29-41. PubMed ID: 16426942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response definitions and European Leukemianet Management recommendations.
    Baccarani M; Castagnetti F; Gugliotta G; Palandri F; Soverini S;
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):331-41. PubMed ID: 19959084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monitoring of bcr/abl fusion gene by interphase-dual-color and dual-fusion fluorescence in situ hybridization in CML after allo-HSCT].
    Qian SX; Li JY; Zhang R; Hong M; Qiu HR; Li L; Xu W; Sheng RL; Wu HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):577-81. PubMed ID: 16800946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.
    Branford S; Cross NC; Hochhaus A; Radich J; Saglio G; Kaeda J; Goldman J; Hughes T
    Leukemia; 2006 Nov; 20(11):1925-30. PubMed ID: 16990771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular methods in diagnosis and monitoring of haematological malignancies.
    Yeung DT; Parker WT; Branford S
    Pathology; 2011 Oct; 43(6):566-79. PubMed ID: 21881536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.
    van Kooten Niekerk PB; Petersen CC; Nyvold CG; Ommen HB; Roug AS; Nederby L; Hokland P; Kjeldsen E
    Br J Haematol; 2014 Jan; 164(1):53-60. PubMed ID: 24903628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standardisation of molecular monitoring for chronic myeloid leukaemia.
    Cross NC
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):355-65. PubMed ID: 19959086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory tools for diagnosis and monitoring response in patients with chronic myeloid leukemia.
    Tohami T; Nagler A; Amariglio N
    Isr Med Assoc J; 2012 Aug; 14(8):501-7. PubMed ID: 22977971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
    Emig M; Saussele S; Wittor H; Weisser A; Reiter A; Willer A; Berger U; Hehlmann R; Cross NC; Hochhaus A
    Leukemia; 1999 Nov; 13(11):1825-32. PubMed ID: 10557058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.